These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 38298504)

  • 1. Evolution of pulmonary hypertension in interstitial lung disease: a journey through past, present, and future.
    Arslan A; Smith J; Qureshi MR; Uysal A; Patel KK; Herazo-Maya JD; Bandyopadhyay D
    Front Med (Lausanne); 2023; 10():1306032. PubMed ID: 38298504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary hypertension inhaled therapies: An updated review.
    El-Kersh K; Jalil BA
    Am J Med Sci; 2023 Jul; 366(1):3-15. PubMed ID: 36921672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plain language summary of the INCREASE study: inhaled treprostinil (Tyvaso) for the treatment of pulmonary hypertension due to interstitial lung disease.
    West N; Smoot K; Patzlaff N; Miceli M; Waxman A
    Future Cardiol; 2023 Apr; 19(5):229-239. PubMed ID: 37466095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical considerations in the management of inhaled prostacyclin therapy for pulmonary hypertension associated with interstitial lung disease (WHO group 3).
    Lee C; Hamlyn J; Porcelli J; Schmit A
    Respir Med; 2022 May; 196():106806. PubMed ID: 35334313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAH-specific therapy for pulmonary hypertension and interstitial lung disease: A systemic review and meta-analysis.
    Zhao N; Chen J; Zhang M; Zhou L; Liu L; Yuan J; Pang X; Hu D; Ren X; Jin Z
    Front Cardiovasc Med; 2022; 9():992879. PubMed ID: 36465444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date.
    Cassady SJ; Almario JAN; Ramani GV
    Drug Healthc Patient Saf; 2024; 16():51-59. PubMed ID: 38855777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment.
    King CS; Shlobin OA
    Chest; 2020 Oct; 158(4):1651-1664. PubMed ID: 32387520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection.
    Parikh R; Konstantinidis I; O'Sullivan DM; Farber HW
    Pulm Circ; 2022 Oct; 12(4):e12141. PubMed ID: 36225536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary Hypertension in Interstitial Lung Disease: Management Options to Move Beyond Supportive Care.
    Fabyan KD; Chandel A; King CS
    Curr Pulmonol Rep; 2023 May; ():1-8. PubMed ID: 37362782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
    Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE
    Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can subcutaneous treprostinil be an alternative for treating pulmonary hypertension in patients with systemic sclerosis-related interstitial lung disease?
    Duarte AC; Alegria S; Vinagre F; Ferreira F; Cordeiro A
    ARP Rheumatol; 2024 Feb; ():. PubMed ID: 38368559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
    Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
    Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interstitial lung disease-associated pulmonary hypertension - what the future holds.
    Cottin V; Diesler R; Turquier S; Valenzuela C
    Curr Opin Pulm Med; 2023 Sep; 29(5):406-415. PubMed ID: 37417835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment.
    Behr J; Nathan SD
    Curr Opin Pulm Med; 2021 Sep; 27(5):396-404. PubMed ID: 34127619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Pulmonary Hypertension Associated with Chronic Lung Disease.
    Blanco I; Hernández-González F; García A; Torres-Castro R; Barberà JA
    Semin Respir Crit Care Med; 2023 Dec; 44(6):826-839. PubMed ID: 37487524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A PrOsPective Cohort Study on Interstitial Lung Disease-Associated Pulmonary Hypertension with a ParticulaR Focus on the Subset with Pulmonary Arterial Hypertension Features (POPLAR Study).
    Tsujino I; Kitahara K; Omura J; Iwahori T; Konno S
    Pulm Ther; 2024 Sep; 10(3):297-313. PubMed ID: 38913242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.
    Nathan SD; Waxman A; Rajagopal S; Case A; Johri S; DuBrock H; De La Zerda DJ; Sahay S; King C; Melendres-Groves L; Smith P; Shen E; Edwards LD; Nelsen A; Tapson VF
    Lancet Respir Med; 2021 Nov; 9(11):1266-1274. PubMed ID: 34214475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.
    Yuan YP; Yuan P; Su YL; Jiang R; Zhang R; He J; Qiu HL; Luo CJ; Liu JM; Gong SG; Wang L; Zhao QH
    Clin Rheumatol; 2022 Jun; 41(6):1675-1686. PubMed ID: 35099674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials in group 3 pulmonary hypertension.
    Harder EM; Waxman AB
    Curr Opin Pulm Med; 2020 Sep; 26(5):391-396. PubMed ID: 32657833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study.
    Waxman A; Restrepo-Jaramillo R; Thenappan T; Engel P; Bajwa A; Ravichandran A; Feldman J; Hajari Case A; Argula RG; Tapson V; Smith P; Deng C; Shen E; Nathan SD
    Eur Respir J; 2023 Jun; 61(6):. PubMed ID: 37080567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.